跳至主要内容
临床试验/CTRI/2021/02/031390
CTRI/2021/02/031390已完成4 期

An active post marketing surveillance to evaluate the safety and efficacy of a fixed-dose combination of Paracetamol 500 mg, Phenylephrine Hydrochloride 10 mg and Chlorpheniramine Maleate 4 mg tablet in symptomatic treatment of common cold in adults.

Zuventus Healthcare Limited0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1.Patients of either gender of age between >=18 years to 60 years.
  • 2.Patients with symptoms of common cold of recent onset, for more than 6 hours and less than 72 hours.
  • 3.Patients willing to give written informed consent.

排除标准

  • 1.Hypersensitivity to any of the ingredients of the formulation.
  • 2.Patients taking a monoamine oxidase inhibitor (MAOI), or barbiturates
  • 3.Pregnancy or breastfeeding women.
  • 4.Patients with hepatocellular insufficiency and in patients with hepatic failure or active liver disease.
  • 5.Patients who took an Antihistamine, Analgesic or Decongestant 1 day prior to study enrollment.
  • 6.Patients otherwise judged to be inappropriate for inclusion in the study by the investigator

研究者

相似试验